Tofen Syrup contains Ketotifen Fumarate 1mg/5ml as the active ingredient.
Ketotifen is an antihistamine medication and a mast cell stabilizer used to treat allergic conditions such as conjunctivitis, asthma, and urticaria (hives).
In addition to treating allergies, ketotifen has shown efficacy in managing systemic mast cell diseases such as mastocytosis and mast cell activation syndrome (MCAS), which involve abnormal accumulation or activation of mast cells throughout the body. Ketotifen is also used for other allergic-type conditions like atopic dermatitis (eczema) and food allergies.
How to take this medication
Recommended dose for 1mg/5mL oral solution : Adults and children >3years old*
Initial: 5 mL twice daily
*Children >3 years old require the same daily dose regimen as adults due to same pattern of metabolism.
Ketotifen may be taken with or without food.
For the oral solution, shake the bottle well before use.
Precautions
For oral ketotifen, the contraindication is for known hypersensitivity to any component of the product.
Caution should be taken on the following conditions:
acute porphyrias (a group of rare disorders that occur when the body cannot make enough of a substance called heme, which is needed for red blood cells to carry oxygen, this causes a build-up of chemicals called porphyrins, which can damage the nerves and the skin) - unlike other histamines, ketotifen appears to be relatively safe in acute porphyria, still, caution should be taken
epilepsy (a disorder causing recurrent seizures) - ketotifen may increase the risk of seizures.
pyloroduodenal obstruction (a condition where the passage of food from the stomach to the small intestine is blocked by something, such as a muscle, an ulcer, a tumor, or a gallstone).
susceptibility to angle-closure glaucoma (a condition where the iris, the colored part of the eye, bulges and blocks the drainage of fluid from the eye, causing high pressure and damage to the optic nerve, which connects the eye to the brain)
urinary retention (inability to urinate).
